evalu
contribut
antimicrobi
use
human
veterinari
medicin
emerg
spread
resist
bacteria
use
substanc
accur
monitor
set
current
variou
initi
collect
sale
data
veterinari
antimicrobi
therebi
provid
overview
quantiti
market
howev
sale
data
collect
level
wholesal
market
author
holder
limit
use
associ
preval
bacteri
resist
speci
level
convert
sale
data
number
potenti
treatment
calv
pig
switzerland
year
use
anim
cours
dose
acd
author
product
number
potenti
therapi
deriv
sale
wholesal
level
acd
mg
per
kg
product
regist
use
multipl
speci
percentag
sale
attribut
author
speci
accord
biomass
distribut
estim
total
therapi
pig
calv
use
number
slaughter
anim
year
denomin
calcul
treatment
intens
therapi
per
pig
per
calf
sale
veterinari
antimicrobi
decreas
calcul
number
potenti
therapi
decreas
pig
calv
analysi
treatment
intens
antimicrobi
class
level
show
decreas
colistin
use
pig
macrolid
use
pig
calv
wherea
use
gener
cephalosporin
calv
decreas
usag
fluoroquinolon
increas
period
correspond
valu
pig
first
extrapol
antimicrobi
usag
product
level
pig
calv
switzerland
show
calv
frequent
treat
pig
decreas
trend
number
therapi
use
colistin
macrolid
cephalosporin
gener
nonetheless
calcul
increas
usag
fluoroquinolon
altogeth
studi
outcom
allow
trend
analysi
use
assess
relationship
antimicrobi
use
resist
nation
level
evalu
contribut
antimicrobi
use
human
veterinari
medicin
emerg
spread
resist
bacteria
use
substanc
accur
monitor
set
current
variou
initi
collect
sale
data
veterinari
antimicrobi
therebi
provid
overview
quantiti
market
howev
sale
data
collect
level
wholesal
market
author
holder
limit
use
associ
preval
bacteri
resist
speci
level
convert
sale
data
number
potenti
treatment
calv
pig
switzerland
year
use
anim
cours
dose
acd
author
product
number
potenti
therapi
deriv
sale
wholesal
level
acd
mg
per
kg
product
regist
use
multipl
speci
percentag
sale
attribut
author
speci
accord
biomass
distribut
estim
total
therapi
pig
calv
use
number
slaughter
anim
year
denomin
calcul
treatment
intens
therapi
per
pig
per
calf
sale
veterinari
antimicrobi
decreas
calcul
number
potenti
therapi
decreas
pig
calv
analysi
treatment
intens
antimicrobi
class
level
show
decreas
colistin
use
pig
macrolid
use
pig
calv
wherea
use
gener
cephalosporin
calv
decreas
usag
fluoroquinolon
increas
period
correspond
valu
pig
first
extrapol
antimicrobi
usag
product
level
pig
calv
switzerland
show
calv
frequent
treat
pig
decreas
trend
number
therapi
use
colistin
macrolid
cephalosporin
gener
nonetheless
calcul
increas
usag
fluoroquinolon
altogeth
studi
outcom
allow
trend
analysi
use
assess
relationship
antimicrobi
use
resist
nation
level
keyword
antibiot
antimicrobi
consumpt
cours
dose
pig
calv
introduct
use
antimicrobi
contribut
emerg
spread
resist
bacteria
human
anim
earli
concern
aros
relat
therapeut
prevent
growthpromot
treatment
foodproduc
anim
fact
antibiot
class
administ
treat
infect
human
anim
one
major
concern
monitor
antimicrobi
usag
therefor
prerequisit
assess
impact
antibiot
treatment
select
spread
bacteri
resist
order
achiev
goal
number
program
monitor
sale
andor
usag
antimicrobi
establish
nation
level
exampl
switzerland
archvet
denmark
intern
level
esvac
project
european
medicin
agenc
program
aim
identif
trend
sale
usag
antimicrobi
class
also
allow
establish
link
chang
observ
resist
monitor
program
therebi
provid
basi
risk
assess
evalu
regulatori
intervent
order
assess
associ
antimicrobi
use
resist
crucial
relev
obtain
consumpt
data
speci
possibl
product
type
level
sever
speci
product
typespecif
factor
impact
relationship
use
resist
factor
includ
age
treatment
age
weight
slaughter
product
avail
per
speci
product
type
especi
product
structur
antimicrobi
sale
data
defin
minim
standard
monitor
program
world
organ
anim
health
offic
intern
de
epizooti
oie
collect
either
manufactur
wholesal
pharmaci
level
depend
nation
distribut
rout
product
sale
data
use
evalu
longterm
trend
includ
inform
dose
rout
administr
indic
durat
therapi
howev
context
resist
epidemiolog
data
actual
use
antimicrobi
collect
either
prescript
patient
level
might
deliv
inform
necessari
establish
evalu
implement
measur
data
current
collect
countri
advanc
collect
system
denmark
netherland
among
european
countri
aact
network
maintain
list
variou
collect
system
alreadi
place
wwwaactingorg
collect
data
anim
level
ultim
goal
antimicrobi
monitor
system
avail
particip
countri
altern
use
normal
sale
data
total
weight
food
produc
anim
popul
denomin
develop
one
denomin
popul
correct
unit
esvac
project
institut
countri
includ
canada
switzerland
archvet
implement
similar
method
surveil
system
usag
antimicrobi
strongli
depend
popul
structur
repartit
high
lowus
speci
normal
weight
may
provid
inform
longterm
trend
time
higher
usag
one
speci
dilut
lower
usag
speciesproduct
type
like
dairi
cow
larg
contribut
overal
livestock
biomass
therefor
import
measur
antibiot
consumpt
near
possibl
end
user
ie
obtain
inform
speci
dosag
durat
whenev
possibl
indic
extrapol
sale
data
use
cours
dose
interim
measur
data
collect
anim
level
cours
dose
indic
propos
anim
cours
dose
acd
french
agenc
food
environment
occup
health
safeti
defin
cours
dose
dcdvet
ema
advantag
acd
productspecif
calcul
therefor
better
repres
nation
specif
dcdvet
unit
acd
establish
product
use
data
summari
product
characterist
spc
contain
necessari
detail
dose
therefor
potenc
durat
use
main
aim
studi
provid
first
time
extrapol
avail
nation
sale
data
number
treat
anim
switzerland
chose
specif
investig
treatment
pig
calv
mainli
rear
treat
group
via
oral
applic
due
lack
detail
data
repartit
sale
made
assumpt
regard
weight
treatment
repartit
sale
data
speci
use
previous
publish
repartit
method
defin
acd
product
contain
antimicrobi
author
switzerland
use
either
pig
calv
combin
inform
nation
antibiot
sale
data
extrapol
number
potenti
treat
anim
year
veterinari
antibiot
sale
data
year
obtain
feder
offic
food
safeti
confidenti
agreement
sinc
sale
data
collect
switzerland
market
author
holder
base
articl
ordin
veterinari
medicin
market
author
holder
requir
deliv
data
everi
product
contain
antimicrobi
sold
calendar
year
product
subject
data
collect
defin
atcvet
code
list
esvac
project
addit
data
antibiot
product
consid
esvac
project
like
spray
product
treat
sensori
organ
also
collect
data
obtain
feder
offic
food
safeti
studi
contain
quantiti
activ
antimicrobi
ingredi
sold
kilogram
product
year
investig
amount
antimicrobi
sold
product
author
singl
speci
directli
assign
target
speci
product
author
one
speci
repartit
determin
use
two
distinct
method
first
one
use
premix
latter
legal
defin
switzerland
veterinari
medicin
product
use
treat
group
anim
incorpor
either
water
feed
ordin
author
medicin
product
art
product
period
safeti
updat
report
psur
contain
data
speci
repartit
submit
swissmed
swiss
agenc
therapeut
product
year
use
premix
repres
product
total
investig
total
sale
anoth
repartit
method
use
oral
solut
oral
powder
inject
repartit
done
accord
biomass
repartit
describ
carmo
et
al
briefli
product
author
one
target
speci
target
speci
assign
percentag
kg
total
sale
repres
proport
biomass
total
biomass
list
author
speci
product
present
studi
food
produc
anim
popul
number
obtain
feder
offic
statist
wwwbfsadminch
number
dog
ani
databas
identita
ag
bern
wwwani
ch
number
cat
swiss
associ
pet
food
produc
verband
heimtiernahrung
bern
wwwvhn
ch
analog
calcul
popul
correct
unit
pcu
esvac
number
slaughter
anim
use
fatten
pig
calv
wherea
data
dairi
cow
sow
sheep
goat
hors
dog
cat
repres
live
anim
throughout
text
tabl
pig
refer
fatten
pig
supplementari
tabl
list
number
anim
weight
use
biomass
repartit
like
weight
treatment
sourc
esvac
report
heavi
anim
rather
low
treatment
intens
like
dairi
cow
skew
biomass
repartit
chose
includ
calcul
either
explicitli
list
author
speci
dairi
cow
withdraw
time
milk
given
spc
product
pig
includ
product
stage
piglet
weaner
use
number
anim
differ
product
stage
present
challeng
promin
one
pig
lack
number
acd
total
quantiti
activ
ingredi
sold
one
year
mg
daili
dose
mg
kg
durat
tratment
day
weight
treatment
kg
therapeut
intens
speci
x
number
acd
speci
x
total
number
anim
speci
x
avail
data
repartit
use
piglet
eg
fatten
pig
antimicrobi
primarili
use
piglet
weaner
colistin
exampl
almost
product
author
pig
data
avail
stratifi
antimicrobi
consumpt
per
differ
age
class
use
sale
data
repartit
data
avail
report
treatment
antimicrobi
switzerland
made
mandatori
end
year
reason
sale
data
includ
use
antimicrobi
age
categori
speci
year
investig
use
slaughter
number
pig
denomin
therapeut
incid
speci
final
inject
product
author
without
indic
product
stage
bovin
contain
dairi
cow
pig
repres
slaughter
pig
sow
use
raw
data
provid
expert
studi
carmo
et
al
determin
use
would
take
place
particular
product
stage
consider
anim
cours
dose
acd
calcul
activ
pharmaceut
ingredi
contain
product
author
year
investig
data
collect
author
summari
product
characterist
enter
ms
excel
sheet
contain
name
product
author
number
list
author
speci
activ
ingredi
dose
durat
dose
given
intern
unit
convert
mg
use
convers
factor
list
esvac
report
whenev
recommend
dose
rang
highest
recommend
dose
longest
durat
chosen
reflect
minim
number
anim
potenti
treat
moreov
differ
dose
author
differ
indic
like
indic
chosen
case
product
present
prophylact
metaphylact
indic
differ
dose
durat
acd
defin
per
kg
acd
per
anim
obtain
multipl
like
weight
treatment
take
swiss
specif
account
weight
treatment
pig
taken
previou
studi
schnetzer
et
al
weight
calv
base
expert
opinion
prof
kask
zurich
person
commun
therapeut
intens
reflect
number
acd
per
slaughter
anim
pig
calf
year
combin
product
number
acd
calcul
separ
activ
pharmaceut
ingredi
therefor
singl
treatment
combin
contain
antimicrobi
result
acd
acd
intens
calcul
use
follow
equat
year
sale
antibiot
use
food
produc
anim
decreas
tabl
time
percentag
repres
premix
decreas
therefor
measur
kg
antimicrobi
sold
premix
made
largest
part
yearli
sale
antimicrobi
veterinari
medicin
consequ
pig
calv
pertin
speci
among
food
produc
anim
investig
use
trend
detect
tonnag
sold
use
speci
decreas
year
investig
compar
pig
calv
howev
normal
number
respect
biomass
produc
slaughter
popul
reveal
much
higher
use
per
kg
biomass
calv
mgkg
biomass
pig
mgkg
biomass
differ
speci
even
increas
higher
calv
normal
sale
data
either
overal
biomass
food
produc
anim
biomass
particular
speci
crude
estim
antimicrobi
use
take
dose
durat
account
therefor
calcul
number
cours
dose
acd
per
product
speci
summari
result
present
tabl
total
number
acd
approxim
time
higher
pig
decreas
year
investig
wherea
decreas
calv
normal
number
slaughter
anim
show
much
slower
decreas
calv
compar
pig
result
differ
speci
grew
year
final
year
investig
antibiot
potenti
impact
resist
select
consequ
treatment
human
anim
moreov
differ
product
author
distinct
condit
pig
calv
repartit
number
acd
per
class
antimicrobi
therefor
calcul
separ
speci
year
tabl
present
repartit
antimicrobi
class
ingredi
sold
premix
parenter
inject
year
polymyxin
form
colistin
class
highest
potenti
number
acd
per
pig
follow
sulfonamid
calv
highest
number
repres
penicillin
mainli
sold
aminopenicillin
follow
tetracyclin
total
number
acd
per
anim
time
higher
calv
pig
calcul
done
inject
product
may
contain
antimicrobi
highest
prioriti
hpcia
avail
oral
applic
pig
highest
number
acd
per
anim
year
repres
macrolid
follow
aminoglycosid
fluoroquinolon
calv
amino
penicillin
class
highest
number
cours
dose
per
anim
follow
macrolid
aminoglycosid
total
number
potenti
acd
per
anim
inject
product
year
calv
pig
final
evolut
number
potenti
acd
per
anim
hpcia
present
tabl
macrolid
use
pig
decreas
product
sold
premix
attenu
correspond
increas
inject
pattern
even
evid
calv
reduct
premix
almost
complet
compens
increas
inject
respect
two
class
hpcia
sale
product
contain
fluoroquinolon
remain
stabl
pig
increas
observ
number
potenti
acd
per
anim
calv
cours
cephalosporin
third
fourth
gener
show
compar
decreas
pig
calv
first
studi
nation
level
use
acd
concept
appli
sale
antimicrobi
object
extrapol
number
potenti
treat
pig
calv
switzerland
sale
antimicrobi
veterinari
medicin
publish
nation
level
sinc
far
data
repres
avail
sourc
exhaust
antimicrobi
consumpt
data
nation
level
sale
figur
may
allow
recognit
trend
lack
inform
potenc
dose
durat
treatment
repartit
per
speci
strongli
limit
use
indic
acd
may
therefor
help
bridg
gap
calcul
acd
repartit
quantiti
product
author
one
speci
would
possibl
without
make
assumpt
might
influenc
result
first
assumpt
relat
weight
anim
standard
weight
impact
calcul
speci
repartit
acd
indic
impact
use
differ
weight
topic
beyond
scope
studi
impact
calcul
studi
elsewher
studi
use
weight
treatment
close
possibl
swiss
realiti
provid
best
fit
result
also
guarante
futur
reproduc
method
comparison
result
weight
like
use
quantifi
swiss
antimicrobi
consumpt
nation
intern
level
approach
compar
one
chosen
esvac
project
method
use
stratifi
antimicrobi
consumpt
product
type
includ
studi
potenti
bia
base
total
biomass
anim
categori
result
estim
highli
depend
anim
demograph
anim
averag
weight
use
might
alway
repres
surrog
product
repartit
categori
reliabl
repartit
gener
data
collect
actual
usag
data
current
avail
switzerland
chose
altern
applic
product
level
would
deliv
reproduc
result
year
accur
possibl
carmo
et
al
compar
three
differ
method
determin
speci
repartit
antimicrobi
longitudin
studi
extrapol
method
base
field
data
applic
singl
product
level
due
requir
minimum
mode
maximum
start
valu
biomass
distribut
shown
method
provid
closest
result
extrapol
base
field
data
therebi
increas
confid
pertin
approach
appli
two
main
drawback
method
depend
defin
averag
weight
countri
specif
anim
demograph
howev
method
limit
data
avail
current
swiss
context
provid
first
insight
antimicrobi
consumpt
pattern
differ
speciesproduct
type
futur
data
collect
system
isabv
descript
avail
http
wwwaactingorgmatrixisabv
shall
provid
insight
pattern
well
basi
comparison
result
method
potenti
bias
make
extrapol
compar
possibl
project
use
standard
weight
esvac
project
must
also
notic
denomin
indic
present
base
number
slaughter
anim
weight
use
calcul
biomass
like
weight
treatment
defin
esvac
project
use
calcul
might
hinder
direct
comparison
studi
taken
consider
benchmark
result
use
biomass
denomin
result
interpret
indic
amount
activ
ingredi
use
per
kg
anim
produc
likewis
therapeut
intens
indic
averag
number
acd
per
anim
producedslaught
high
proport
heavier
anim
like
cow
altern
high
treatment
intens
speci
lower
biomass
exampl
anim
demograph
bia
result
stratif
approach
base
biomass
repartit
across
speci
mainli
influenc
nation
product
structur
switzerland
dairi
product
import
agricultur
sector
therefor
dairi
cow
make
high
proport
food
produc
anim
sector
cow
repres
total
biomass
year
high
proport
lead
underestim
repartit
sale
pig
calv
primarili
affect
repartit
aminoglycosid
cephalosporin
third
gener
antimicrobi
frequent
use
treatment
dairi
cow
calcul
number
acd
per
anim
class
present
tabl
therefor
underestim
within
speci
biomass
repartit
could
use
estim
use
antimicrobi
differ
product
stage
pig
howev
use
piglet
weaner
fatten
pig
produc
year
introduc
bia
count
signific
undefin
proport
anim
two
three
time
sale
data
avail
one
full
year
therefor
chose
base
repartit
well
denomin
treatment
intens
number
pig
slaughter
year
indic
use
studi
surrog
pig
product
stage
number
acd
repres
extrapol
usag
data
base
sale
figur
follow
latter
close
downward
trend
sale
mirror
treatment
number
calv
pig
howev
differ
becom
evid
soon
addit
factor
like
applic
rout
taken
account
repartit
pig
year
show
activ
ingredi
use
parenter
base
quantiti
wherea
repres
treatment
use
acd
main
reason
differ
lie
potenc
activ
ingredi
antimicrobi
use
parenter
lower
dose
loss
activ
ingredi
compar
lower
bioavail
follow
oral
applic
anoth
possibl
reason
use
one
acd
parenter
appli
combin
product
inject
product
investig
combin
two
activ
ingredi
wherea
approach
disput
show
higher
number
treatment
think
use
acd
better
suit
test
associ
antimicrobi
use
resist
convert
sale
antimicrobi
number
treatment
per
anim
allow
detect
trend
would
obviou
assess
quantiti
activ
ingredi
sold
macrolid
use
treat
calv
provid
good
exampl
result
show
clear
shift
oral
applic
form
premix
toward
increas
use
inject
one
possibl
explan
increas
avail
macrolid
antibiot
long
durat
action
eg
tulathromycin
tildipirosin
gamithromycin
activ
compound
combin
easi
use
singl
applic
long
action
moreov
parenter
applic
time
maxim
concentr
mainten
activ
level
influenc
appetit
anim
therefor
guarante
adequ
treatment
sick
anim
reduc
appetit
neg
side
studi
macrolid
use
human
medicin
convincingli
show
higher
level
resist
select
longer
act
molecul
result
show
strong
differ
extrapol
usag
antimicrobi
pig
calv
explain
singl
factor
administr
antimicrobi
driven
medic
econom
also
psychosoci
factor
crowd
effect
stress
transport
young
yet
immunocompet
anim
partial
inadequ
colostrum
feed
less
ideal
stabl
climat
among
factor
favor
respiratori
problem
calv
swine
industri
abovement
factor
also
exist
structur
manag
pig
product
limit
risk
manag
practic
like
allinallout
includ
disinfect
batch
integr
product
piglet
finish
strongli
help
reduc
antimicrobi
usag
pig
two
main
period
risk
treatment
antimicrobi
first
wean
around
kg
bodi
weight
second
around
kg
bodi
weight
pig
diarrhea
one
lead
indic
treatment
unspecif
symptom
mani
differ
caus
includ
bacteri
also
dietari
viral
origin
context
avail
vaccin
circoviru
lawsonia
intracellulari
infect
year
contribut
reduct
diarrheal
symptom
henc
rather
indiscrimin
use
antibiot
treat
symptom
calv
respiratori
diseas
much
multifactori
introduct
variou
vaccin
bovin
respiratori
syncyti
parainfluenza
corona
viru
seem
posit
effect
pig
industri
sever
factor
hinder
proper
comparison
result
previous
publish
data
best
knowledg
first
time
acd
indic
use
nation
level
switzerland
matter
fact
use
current
widespread
countri
except
franc
develop
howev
comparison
french
data
difficult
public
present
french
antimicrobi
consumpt
use
acd
per
anim
year
indic
french
indic
exposur
antimicrobi
alea
anim
level
exposur
antimicrobi
obtain
divid
effect
treat
biomass
total
biomass
speci
global
alea
calcul
year
franc
repres
decreas
compar
anoth
difficulti
use
differ
product
categori
standard
weight
treatment
pig
french
system
use
weight
kg
specif
categori
sow
averag
pig
popul
set
kg
time
higher
standard
weight
treatment
kg
identifi
previou
swiss
studi
use
differ
standard
weight
treatment
also
explain
discrep
antimicrobi
consumpt
franc
publish
year
esvac
report
mgpcu
ans
report
mgkg
due
differ
weight
categori
difficulti
make
assumpt
extrapol
decid
compar
figur
french
one
data
compar
countri
calv
rear
product
veal
meat
besid
franc
belgium
countri
could
find
adequ
data
comparison
product
system
also
exist
netherland
avail
report
year
use
indic
differ
one
present
studi
still
show
higher
treatment
intens
calv
compar
pig
line
present
studi
antimicrobi
use
higher
calv
pig
exampl
clearli
illustr
need
harmon
methodolog
intern
level
order
discuss
data
collect
differ
countri
discuss
current
take
place
within
aactng
network
wwwaactingorg
first
studi
number
treatment
pig
calv
extrapol
yearli
sale
show
similar
differ
two
speci
consider
wherea
sale
speci
number
extrapol
treatment
decreas
similar
way
differ
number
treatment
per
anim
pig
calv
differ
year
investig
given
appli
method
base
extrapol
sale
figur
similar
decreas
speci
level
expect
howev
use
cours
dose
allow
investig
trend
pattern
antimicrobi
treatment
studi
clear
class
macrolid
decreas
oral
use
partli
pig
complet
calv
compens
applic
long
act
inject
therefor
recommend
use
extrapol
treatment
number
exhaust
collect
usag
data
place
concept
acd
also
complement
collect
antimicrobi
consumpt
data
speci
level
allow
valid
use
sale
data
dataset
gener
studi
includ
manuscriptsupplementari
file
rs
calcul
present
work
lc
help
repartit
sale
speci
expert
advic
biomass
distribut
raw
sale
data
advic
regard
use
provid
dh
studi
design
cm
supervis
ke
hn
